A Study to Assess the Long-Term Safety of Tacrolimus Cream in the Treatment of Psoriasis
NCT ID: NCT00293917
Last Updated: 2008-02-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
658 participants
INTERVENTIONAL
2006-01-31
2007-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis
NCT00293891
A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis
NCT00293930
Efficacy and Safety of TC Cream In Treating Patients With Psoriasis Vulgaris
NCT03372811
Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)
NCT04053387
Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test
NCT03004339
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tacrolimus Cream
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Disease on only scalp
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma US, Inc.
INDUSTRY
Astellas Pharma Inc
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
M Rico, MD
Role: STUDY_DIRECTOR
Astellas Pharma US, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Fresno, California, United States
Santa Monica, California, United States
Vista, California, United States
Jacksonville, Florida, United States
Miami, Florida, United States
Atlanta, Georgia, United States
Newnan, Georgia, United States
Boise, Idaho, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Louisville, Kentucky, United States
New Orleans, Louisiana, United States
Boston, Massachusetts, United States
Detroit, Michigan, United States
Minneapolis, Minnesota, United States
Lincoln, Nebraska, United States
Reno, Nevada, United States
Lebanon, New Hampshire, United States
East Windsor, New Jersey, United States
East Setauket, New York, United States
New York, New York, United States
New York, New York, United States
Hershey, Pennsylvania, United States
Simpsonville, South Carolina, United States
Goodlettsville, Tennessee, United States
Arlington, Texas, United States
Houston, Texas, United States
Bellingham, Washington, United States
Kenatchee, Washington, United States
Spokane, Washington, United States
Winnipeg, Manitoba, Canada
St. John's, Newfoundland and Labrador, Canada
Halifax, Nova Scotia, Canada
Hamilton, Ontario, Canada
Markham, Ontario, Canada
Windsor, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
04-0-207
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.